Literature DB >> 22080965

Durable complete remission after single agent decitabine in AML relapsing in extramedullary sites after allo-SCT.

S N Singh, Q Cao, I Gojo, A P Rapoport, G Akpek.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22080965     DOI： 10.1038/bmt.2011.210

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  10 in total

Review 1.  Hypomethylating agents after allogeneic blood stem cell transplantation.

Authors:  Thomas Schroeder; Christina Rautenberg; Rainer Haas; Guido Kobbe
Journal:  Stem Cell Investig       Date:  2016-11-28

Review 2.  Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation.

Authors:  Thomas Schroeder; Christina Rautenberg; Rainer Haas; Ulrich Germing; Guido Kobbe
Journal:  Int J Hematol       Date:  2017-11-15       Impact factor: 2.490

3.  Primary vaginal myeloid sarcoma: a rare case report and review of the literature.

Authors:  Gaurang Modi; Irappa Madabhavi; Harsha Panchal; Apurva Patel; Asha Anand; Sonia Parikh; Pritam Jain; Swaroop Revannasiddaiah; Malay Sarkar
Journal:  Case Rep Obstet Gynecol       Date:  2015-01-18

4.  An unusual type of myeloid sarcoma localization following myelofibrosis: A case report and literature review.

Authors:  Nicola Orofino; Daniele Cattaneo; Cristina Bucelli; Loredana Pettine; Sonia Fabris; Umberto Gianelli; Nicola Stefano Fracchiolla; Agostino Cortelezzi; Alessandra Iurlo
Journal:  Leuk Res Rep       Date:  2017-07-27

5.  Low-dose decitabine enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by re-modulating the tumor microenvironment.

Authors:  Ganjun Yu; Yanfeng Wu; Wenying Wang; Jia Xu; Xiaoping Lv; Xuetao Cao; Tao Wan
Journal:  Cell Mol Immunol       Date:  2018-04-05       Impact factor: 11.530

6.  Long-Lasting Remission in De Novo Breast Myeloid Sarcoma Treated with Decitabine and Radiotherapy.

Authors:  Carla Minoia; Vincenza de Fazio; Giovanni Scognamillo; Anna Scattone; Nicola Maggialetti; Cristina Ferrari; Attilio Guarini
Journal:  Diagnostics (Basel)       Date:  2019-07-27

Review 7.  Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Authors:  Kah Keng Wong; Rosline Hassan; Nik Soriani Yaacob
Journal:  Front Oncol       Date:  2021-02-25       Impact factor: 6.244

8.  Successful Treatment of Myeloid Sarcoma in an Elderly Patient with Myelodysplastic Syndrome with Reduced-Dose Azacitidine.

Authors:  Kazuya Sato; Nodoka Tsukada; Junki Inamura; Shigetsuna Komatsu; Keisuke Sato; Masayo Yamamoto; Motohiro Shindo; Kentaro Moriichi; Yusuke Mizukami; Mikihiro Fujiya; Yoshihiro Torimoto; Toshikatsu Okumura
Journal:  Case Rep Hematol       Date:  2021-04-21

9.  Clinical characteristics, treatment, and prognosis of 118 cases of myeloid sarcoma.

Authors:  Haiqiu Zhao; Zhenkun Dong; Dingming Wan; Weijie Cao; Haizhou Xing; Zhenzhen Liu; Jixin Fan; Haiqiong Wang; Runqing Lu; Yinyin Zhang; Qianqian Cheng; Zhongxing Jiang; Fei He; Xinsheng Xie; Rong Guo
Journal:  Sci Rep       Date:  2022-04-26       Impact factor: 4.996

10.  Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors.

Authors:  Carmine Liberatore; Maria Teresa Lupo Stanghellini; Francesca Lorentino; Luca Vago; Matteo Giovanni Carrabba; Raffaella Greco; Sarah Marktel; Andrea Assanelli; Francesca Farina; Consuelo Corti; Massimo Bernardi; Jacopo Peccatori; Katja Sockel; Jan Moritz Middeke; Johannes Schetelig; Anika Bergmann; Christina Rautenberg; Fabio Ciceri; Martin Bornhäuser; Thomas Schroeder; Friedrich Stölzel
Journal:  Ther Adv Hematol       Date:  2022-06-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.